20:11 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three...
21:18 , Jul 31, 2018 |  BC Innovations  |  Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
18:22 , Jul 26, 2018 |  BC Innovations  |  Translation in Brief

A plasticity problem

New research from the University of Bordeaux suggests the synaptic pathology underlying Alzheimer’s disease is driven by aberrant activation of CAMK2 by β-amyloid oligomers. The findings may point to the missing link in how β-amyloid...
19:04 , Jun 6, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A mutation in CAMK2A could help predict the risk of a previously undescribed neurodevelopmental disorder characterized by growth delay, frequent seizures and severe cognitive dysfunction. Genomic profiling of two children with the...
20:01 , Feb 1, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018...
21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); pain Mouse studies suggest inhibiting CAMK2A could help treat MS, including MS-associated pain. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, knock-in of an autophosphorylation-deficient CAMK2A variant or intrathecal...
22:57 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Rat studies suggest inhibiting CAMK2 could help treat hypertension. In a rat model of hypertension, injection of a CAMK2 inhibitor tool peptide into the hypothalamic paraventricular nucleus decreased arterial blood pressure and sympathetic...
19:01 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting CAMK2G could help treat atherosclerosis. In arterial plaque-associated macrophages from patients with carotid artery stenosis, levels of activated CAMK2G were higher in patients with stroke symptoms...
21:16 , Feb 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy Cell culture studies suggest inhibiting CAMK2 could help treat epilepsy. In a synaptic transmission assay in primary hippocampal pyramidal neurons from a mouse model of epilepsy, a CAMK2 inhibitor tool compound decreased persistent...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); calcium calmodulin-dependent protein kinase II (CAMK2)

Cardiovascular disease INDICATION: Heart failure Cell culture and mouse studies suggest inhibiting RIPK3 or CAMK2 could help treat heart failure. Levels of RIPK3 and RIPK3-phosphorylated CAMK2 were higher in rat ventricular myocytes under hypoxic conditions...